What Distinguishes Successful Schizophrenia Clinical Development Programs From Those That do not Progress Beyond Phase II?
In this expert discussion, Dr. Jeffrey A. Lieberman, who led the landmark CATIE trial and serves as co-chair of Signant's psychiatry scientific advisory board, moderates a distinguished panel of CNS specialists to examine this critical question.
Drawing from recent trial experiences and leveraging new opportunities made possible by AI technology and methodological innovations, our experts share practical approaches to de-risking schizophrenia clinical trials.
Discover evidence-based strategies for optimizing patient selection criteria, enhancing site selection and investigator training for CNS endpoints, improving psychiatric assessment reliability, implementing digital measurement solutions, and successfully navigating the crucial transition from Phase II to Phase III.
Whether you're planning your next schizophrenia study or looking to strengthen existing programs, this session provides actionable insights to help increase your chances of clinical development success.
